'%2F%3E%3Cpath%20d%3D'M11%205H21M13.5%205V11.6A8.5%208.5%200%201%200%2018.5%2011.6V5'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'3.4'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Cpath%20d%3D'M10.6%2019.6L13.9%2021.8L17.6%2018.4L21.4%2020.4'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'2.6'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Ccircle%20cx%3D'17.6'%20cy%3D'18.4'%20r%3D'2.6'%20fill%3D'%23fff'%2F%3E%3C%2Fsvg%3E){kind=small}
Sunrest Lifescience Limited
SUNREST (NSE) · ISIN INE0PLZ01012 · Pharmaceuticals · listed 2023
Not on any surveillance list
In Q2 FY25 (quarter to 30 September 2024, standalone), revenue was ₹15.39 cr and profit after tax ₹0.58 cr. Revenue was 23.4% higher than in Q2 FY24.
Open the full company file Every section, filings and your notes, in the app.
Quarterly results
| Quarter | Revenue | Profit after tax | EPS (₹) | Filed |
|---|---|---|---|---|
| Q2 FY25 standalone | ₹15.39 cr | ₹0.58 cr | 2.71 | 15 Nov 2024 |
| Q2 FY24 standalone | ₹12.47 cr | ₹1.99 cr | 6.62 | 10 Jun 2024 |
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 31 Mar 2026 standalone | ₹19.27 cr | ₹9.17 cr | ₹41.35 cr |
| 30 Sep 2025 standalone | ₹17.34 cr | ₹7.91 cr | ₹36.17 cr |
| 31 Mar 2025 standalone | ₹16.19 cr | ₹6.16 cr | ₹35.16 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 53.50% | 0.00% | 0.00% | 46.50% |
Latest filings
- Sunrest Lifescience Limited has informed the Exchange regarding Outcome of Board Meeting held on September 11, 2026 in relation to Dissolving the Right Issue due to non receipt of minimum subscription 11 September 2026 · NSE
- Sunrest Lifescience Limited has informed the Exchange that Board of Directors at its meeting held on September 02, 2026, has decided to extend the issue of equity shares on rights basis in the ratio o 2 September 2026 · NSE
- Annual Report FY2025-26 (New) 13 August 2026 · NSE
- Outcome of Board Meeting held on 12th August, 2026 12 August 2026 · NSE
- Sunrest Lifescience Limited has informed the Exchange that Board of Directors at its meeting held on August 07, 2026, has decided to issue equity shares on rights basis in the ratio of 1 : 1, i.e 1 Eq 7 August 2026 · NSE
Other companies in Pharmaceuticals
- Lupin Limited
- Sun Pharmaceutical Industries Limited
- Cipla Limited
- Dr. Reddy's Laboratories Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Aurobindo Pharma Limited
- Divi's Laboratories Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 29 October 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.